Express Pharma
Home  »  Latest Updates  »  Pharmapack success points to sizeable growth potential for global drug delivery and packaging in 2019

Pharmapack success points to sizeable growth potential for global drug delivery and packaging in 2019

11

Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019

The drug delivery and healthcare packaging industry is set for significant growth in 2019 as Pharmapack Europe recently welcomed a record 410 exhibiting companies and nearly 5,500 attendees from 75 countries. The pharmaceutical packaging and drug delivery event held of late oin Europe saw a diversification of innovations and new drug delivery solutions, with ‘patient-centricity’ emerging as the central theme.

A who’s who of pharma packaging and delivery innovators exhibited at Pharmapack from BD and Baumann to Nemera, Aptar, SFM Medical Devices, SHL, Vetter and West Pharmaceutical Services. Beyond these global giants, the event also played host to emerging innovators in the start-up hub – showcasing new technologies from AI development platforms and advanced data analytics to miniaturised packaging sensors, soft mist inhalers and smart packaging.

Pharmapack is widely acknowledged as a window into upcoming industry trends with sustainability, eco-friendly packaging and smart packaging, in particular earmarked for 2019. Highlighting renowned innovations, the Pharmapack Awards returned with a record number of entries, while the Innovation Gallery showcased a range of new technologies-from child-resistant pumps, and anti-tampering labels to connected and dual delivery devices, disposable autoinjectors and Augmented Reality on smartphones.

The conference witnessed deliberations on major industry changes that lie ahead, including how to lower development costs whilst increasing sustainability. Gregor Anderson, Managing Director, Pharmacentric Solutions, suggested that “we could potentially further improve sustainability in device design and sourcing by working earlier with suppliers, so they can engineer out costs and environmental impact”. He added that harnessing the consumers’ growing environmental conscience and asking them to return inhalers to a pharmacy after use for recycling could “deliver tremendous results when factoring in just how many inhalers are disposed of each year”.

Another green approach discussed at the event was replacing PVC in secondary packaging, and Yves Steffen, Head of Packaging and Devices in biological technical development and manufacturing at Novartis, expects an industry-wide change to ‘plastic neutral’.

But several of the sustainability panel’s experts also forewarned that primary packaging will remain a challenge, as it needs stability testing, which takes a long time to develop and implement. In particular, Guilhem Rousselet, incharge for Global Packaging and Serialization – Industrial Affairs at Sanofi added “there is just not yet any industry solution to replace PVC as the material of choice – we are still some way off this”.

In a separate session on ‘what’s new in biologicals and biosimilar drug delivery devices’, experts agreed that technology is already there to collect data, but that the biggest potential hurdle is upscaling of new devices and issues around patient privacy. David Braun, Global Head of medical device and digital health business solutions at Merck, postulated that the adoption rate of connected devices is slow due to ‘high costs, complicated GUIs and lack of patient awareness’. Experts forecast that ‘closed loop digitisation’, such as heart monitoring is the future, and the biggest challenge will be managing the integrity of the data created.

Concerns around patient data were shared throughout the conference, with Alex Driver, Senior Consultant at Team Consulting, taking a particularly interesting angle on the situation. He believes that while people are concerned with how their data is being used, they still actively use connected devices, such as phones due to the value of the device outweighing potential concerns. He argues that if a patient is forgoing their privacy in order to use a connected device, healthcare companies simply need to incentivise patients to use the system by potentially shifting patient behaviour with optimum design.

Silvia Forroova, Brand Director at Pharmapack Europe commented, “This year’s event demonstrated what an exciting time it is for drug delivery and packaging. I anticipate many of the innovations seen on the show floor this week delivering improvements in patient care over the next few years – in particular those across patient friendly and sustainable solutions. The conference agenda showed the depth and breadth of new developments and 2019 looks set to bring a golden age of patient focused developments and innovations from smart packaging and connected devices to autoinjectors. Our agenda also highlighted the importance of partnering to bring newer innovations to market, meeting new contacts who can help scale-up promising technologies beyond clinical development and into commercial supply. This is why an event like Pharmapack remains so crucial to industry innovation moving forwards; it’s about meeting contacts, exchanging ideas and learning vital new skills to help further the industry so we can deliver new solutions for patients globally”.

Comments are closed.